UMass Chan Affiliations
Department of PsychiatryDocument Type
Journal ArticlePublication Date
2004-05-25Keywords
AnimalsBlood-Brain Barrier
Clinical Trials as Topic
Combined Modality Therapy
Comorbidity
Drug Administration Routes
Drug Design
Drug Evaluation, Preclinical
Drug Therapy, Combination
Health Education
Humans
Marketing
Mental Disorders
Nicotine
effects
Nicotinic Antagonists
Rats
Smoking
Smoking Cessation
Social Support
Substance Withdrawal Syndrome
Tobacco Use Disorder
Vaccines
Psychiatry
Metadata
Show full item recordAbstract
The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.Source
Expert Opin Emerg Drugs. 2004 May;9(1):39-53. Link to article on publisher's siteDOI
10.1517/eoed.9.1.39.32951Permanent Link to this Item
http://hdl.handle.net/20.500.14038/45659PubMed ID
15155135Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1517/eoed.9.1.39.32951